Cabaletta Bio Company

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Technology: CAR-T
Industry: Biotechnology, Health Care, Medical, Public, Robotics, Therapeutics
Headquarters: Philadelphia, Pennsylvania, United States
Founded Date: 2017-06-01
Employees Number: 1-10
Funding Status: IPO
Investors Number: 8
Total Funding: 88000000
Estimated Revenue: $1M to $10M
Last Funding Date: 2019-01-03
Last Funding Type: Series B

Visit Website
https://twitter.com/cabalettabio
Register and Claim Ownership